Cargando…
Economic Burden of Multiple Sclerosis Drugs in Iran during 2011–2019
BACKGROUND: Due to the invariably progressive nature of multiple sclerosis (MS) and the high economic burden of chronic diseases, this study was performed to estimate the economic burden of MS medications in Iran. METHODS: The present research is a descriptive study performed using comprehensive nat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113575/ https://www.ncbi.nlm.nih.gov/pubmed/37089141 http://dx.doi.org/10.18502/ijph.v52i2.11894 |
_version_ | 1785027869866459136 |
---|---|
author | Asadollahi, Mina Darvishi, Ali Azimi, Amirreza Annabi, Majid Jafariazar, Zahra Heshmat, Ramin |
author_facet | Asadollahi, Mina Darvishi, Ali Azimi, Amirreza Annabi, Majid Jafariazar, Zahra Heshmat, Ramin |
author_sort | Asadollahi, Mina |
collection | PubMed |
description | BACKGROUND: Due to the invariably progressive nature of multiple sclerosis (MS) and the high economic burden of chronic diseases, this study was performed to estimate the economic burden of MS medications in Iran. METHODS: The present research is a descriptive study performed using comprehensive national data of Iran's Health Insurance Organization (IHIO). The timeframe for study was 2011–2019. In order to calculate the economic burden of MS medications, the cost of illness (COI) method based on the prevalence approach was used. In this study, economic burden estimation was performed according to available data on medication costs. Data mining was also used to perform different stages of study. RESULTS: The number of patients receiving MS medications covered by IHIO has increased from 19,367 in 2011 to 50,642 in 2019. The economic burden of MS medications of patients covered by the IHIO increased from $81 million to $96 million between 2011 and 2019, respectively. Among the 9 medications studied, Interferon accounted for a very high share of costs in all years. The cost per patient receiving medication has also increased from $7,000 in 2011 to $18,000 in 2019. CONCLUSION: Calculations of the economic burden of MS medications in Iran showed an upward trend during the 9 years of the study, which due to the increasing number of patients in Iran, the arrival of new medications and also the increase in prices. |
format | Online Article Text |
id | pubmed-10113575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Tehran University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-101135752023-04-20 Economic Burden of Multiple Sclerosis Drugs in Iran during 2011–2019 Asadollahi, Mina Darvishi, Ali Azimi, Amirreza Annabi, Majid Jafariazar, Zahra Heshmat, Ramin Iran J Public Health Original Article BACKGROUND: Due to the invariably progressive nature of multiple sclerosis (MS) and the high economic burden of chronic diseases, this study was performed to estimate the economic burden of MS medications in Iran. METHODS: The present research is a descriptive study performed using comprehensive national data of Iran's Health Insurance Organization (IHIO). The timeframe for study was 2011–2019. In order to calculate the economic burden of MS medications, the cost of illness (COI) method based on the prevalence approach was used. In this study, economic burden estimation was performed according to available data on medication costs. Data mining was also used to perform different stages of study. RESULTS: The number of patients receiving MS medications covered by IHIO has increased from 19,367 in 2011 to 50,642 in 2019. The economic burden of MS medications of patients covered by the IHIO increased from $81 million to $96 million between 2011 and 2019, respectively. Among the 9 medications studied, Interferon accounted for a very high share of costs in all years. The cost per patient receiving medication has also increased from $7,000 in 2011 to $18,000 in 2019. CONCLUSION: Calculations of the economic burden of MS medications in Iran showed an upward trend during the 9 years of the study, which due to the increasing number of patients in Iran, the arrival of new medications and also the increase in prices. Tehran University of Medical Sciences 2023-02 /pmc/articles/PMC10113575/ /pubmed/37089141 http://dx.doi.org/10.18502/ijph.v52i2.11894 Text en Copyright © 2023 Asadollahi et al. Published by Tehran University of Medical Sciences https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited. |
spellingShingle | Original Article Asadollahi, Mina Darvishi, Ali Azimi, Amirreza Annabi, Majid Jafariazar, Zahra Heshmat, Ramin Economic Burden of Multiple Sclerosis Drugs in Iran during 2011–2019 |
title | Economic Burden of Multiple Sclerosis Drugs in Iran during 2011–2019 |
title_full | Economic Burden of Multiple Sclerosis Drugs in Iran during 2011–2019 |
title_fullStr | Economic Burden of Multiple Sclerosis Drugs in Iran during 2011–2019 |
title_full_unstemmed | Economic Burden of Multiple Sclerosis Drugs in Iran during 2011–2019 |
title_short | Economic Burden of Multiple Sclerosis Drugs in Iran during 2011–2019 |
title_sort | economic burden of multiple sclerosis drugs in iran during 2011–2019 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113575/ https://www.ncbi.nlm.nih.gov/pubmed/37089141 http://dx.doi.org/10.18502/ijph.v52i2.11894 |
work_keys_str_mv | AT asadollahimina economicburdenofmultiplesclerosisdrugsiniranduring20112019 AT darvishiali economicburdenofmultiplesclerosisdrugsiniranduring20112019 AT azimiamirreza economicburdenofmultiplesclerosisdrugsiniranduring20112019 AT annabimajid economicburdenofmultiplesclerosisdrugsiniranduring20112019 AT jafariazarzahra economicburdenofmultiplesclerosisdrugsiniranduring20112019 AT heshmatramin economicburdenofmultiplesclerosisdrugsiniranduring20112019 |